NLM Digital Collections

Search

Start Over Subjects Treatment Outcome ✖Remove constraint Subjects: Treatment Outcome

21. Mémoire à consulter pour M. Jules Guérin, contre MM. Malgaigne, Vidal (de Cassis) et Henroz

Publication:
[Paris] : Imprimerie et lithographie de Félix Malteste et Cie, [1844]
Subject(s):
Hospital Departments
Orthopedics
Treatment Outcome
Orthopedic Procedures -- methods
Professional Misconduct
Dissent and Disputes
Periodicals as Topic
Paris
Guérin, Jules, 1801-1886.
Malgaigne, J.-F. (Joseph-François), 1806-1865.
Vidal, Auguste-Théodore, 1803-1856.
Henroz, J. A.

24. The comparative clinical effectiveness and value of simeprevir and sofosbuvir in the treatment of chronic hepatitis C infection: a technology assessment : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Pearson, Steven D., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, April 15, 2014
Subject(s):
Comparative Effectiveness Research
Hepatitis C, Chronic -- drug therapy
Heterocyclic Compounds, 3-Ring -- therapeutic use
Sulfonamides -- therapeutic use
Uridine Monophosphate -- analogs & derivatives
Uridine Monophosphate -- therapeutic use
Antiviral Agents -- economics
Antiviral Agents -- therapeutic use
Cost-Benefit Analysis
Drug Costs
Drug Therapy, Combination
Genotype
Hepatitis C -- economics
Hepatitis C -- genetics
Heterocyclic Compounds, 3-Ring -- adverse effects
Heterocyclic Compounds, 3-Ring -- economics
Insurance Coverage
Interferon-alpha -- therapeutic use
Oligopeptides -- therapeutic use
Polyethylene Glycols -- therapeutic use
Proline -- analogs & derivatives
Proline -- therapeutic use
Protease Inhibitors -- economics
Protease Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Ribavirin -- therapeutic use
Sulfonamides -- adverse effects
Technology Assessment, Biomedical
Treatment Outcome
Uridine Monophosphate -- adverse effects
Uridine Monophosphate -- economics
Value-Based Purchasing
Humans
United States

25. Management of patients with opioid dependence: a review of clinical, delivery system, and policy options

Publication:
[Boston, MA] : Institute for Clinical and Economic Review, July 2014
Subject(s):
Analgesics, Opioid -- therapeutic use
Buprenorphine -- therapeutic use
Comparative Effectiveness Research
Delivery of Health Care
Health Policy
Methadone -- therapeutic use
Naloxone -- therapeutic use
Naltrexone -- therapeutic use
Opiate Substitution Treatment -- economics
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- economics
Opioid-Related Disorders -- rehabilitation
Analgesics, Opioid -- administration & dosage
Analgesics, Opioid -- adverse effects
Budgets
Cohort Studies
Cost-Benefit Analysis
Counseling
Criminal Law
Drug Combinations
Drug Costs
Health Services Accessibility
Insurance Coverage
Medicaid
Medicare
Patient Care Team
Patient-Centered Care
Practice Guidelines as Topic
Treatment Outcome
Humans
New England
United States

26. Controversies in the management of patients with type 2 diabetes: final report

Publication:
[Boston, MA] : Institute for Clinical and Economic Review, December 2014
Subject(s):
Comparative Effectiveness Research
Diabetes Mellitus, Type 2 -- drug therapy
Disease Management
Blood Glucose -- analysis
Blood Glucose -- metabolism
Dipeptidyl-Peptidase IV Inhibitors -- therapeutic use
Drug Therapy, Combination
Hemoglobin A, Glycosylated -- analysis
Hypoglycemic Agents -- administration & dosage
Hypoglycemic Agents -- therapeutic use
Insulin -- therapeutic use
Metformin -- administration & dosage
Metformin -- therapeutic use
Monitoring, Ambulatory
Randomized Controlled Trials as Topic
Receptors, Glucagon -- agonists
Sulfonylurea Compounds -- administration & dosage
Sulfonylurea Compounds -- therapeutic use
Treatment Outcome
Humans
New England
United States

27. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks : final report

Author(s):
Tice, Jeffrey A., author
Ollendorf, Daniel A., author
Cunningham, Courtney, author
Pearson, Steven D., author
Kazi, Dhruv S., author
Coxson, Pamela G., author
Moran, Andrew E., author
Penko, Joanne, author
Guzman, David, author
Bibbins-Domingo, Kirsten, author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, November 24, 2015
Subject(s):
Anticholesteremic Agents -- therapeutic use
Azetidines -- therapeutic use
Enzyme Inhibitors -- therapeutic use
Hypercholesterolemia -- therapy
Hyperlipoproteinemia Type II -- prevention & control
Proprotein Convertases -- economics
Serine Endopeptidases -- economics
Cholesterol, LDL
Cost-Benefit Analysis
Decision Support Techniques
Drug Costs
Drug Resistance
Practice Guidelines as Topic
Randomized Controlled Trials as Topic
Technology Assessment, Biomedical
Treatment Outcome
Value-Based Purchasing
Humans
New England
United States

28. Obeticholic acid for the treatment of primary biliary cholangitis: comparative clinical effectiveness, value, and value-based price benchmarks : evidence report

Author(s):
Pearson, Steven D., author
Banken, Reiner, author
Chapman, Rick, author
Emond, Sarah K., author
Loos, Anne M., author
Russo, Elizabeth T., author
Segel, Celia S., author
Ollendorf, Daniel A., author
Chhatwal, Jagpreet, author
Hur, Chin, author
Klebanoff, Matthew, author
Samur, Sumeyye, author
Publication:
Boston, MA : Institute for Clinical and Economic Review, March 2016
Subject(s):
Bile Acids and Salts -- agonists
Cholangitis -- drug therapy
Comparative Effectiveness Research
Value-Based Purchasing
Benchmarking
Bile Acids and Salts -- adverse effects
Bile Acids and Salts -- economics
Cost-Benefit Analysis
Liver Cirrhosis -- prevention & control
Liver Transplantation
Pruritus
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

29. Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness and value : final evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 6, 2017
Subject(s):
Comparative Effectiveness Research
Multiple Sclerosis, Chronic Progressive -- drug therapy
Multiple Sclerosis, Relapsing-Remitting -- drug therapy
Antirheumatic Agents -- adverse effects
Antirheumatic Agents -- economics
Antirheumatic Agents -- therapeutic use
Benchmarking
Cost-Benefit Analysis
Immunosuppressive Agents -- adverse effects
Immunosuppressive Agents -- economics
Immunosuppressive Agents -- therapeutic use
Insurance Coverage
Randomized Controlled Trials as Topic
Treatment Outcome
Humans
United States

30. Targeted immune modulators for rheumatoid arthritis: effectiveness & value : evidence report

Publication:
Boston, MA : Institute for Clinical and Economic Review, March 10, 2017
Subject(s):
Arthritis, Rheumatoid -- drug therapy
Comparative Effectiveness Research
Immunologic Factors -- therapeutic use
Abatacept -- therapeutic use
Adalimumab -- therapeutic use
Certolizumab Pegol -- therapeutic use
Cost-Benefit Analysis
Etanercept -- therapeutic use
Immunologic Factors -- adverse effects
Immunologic Factors -- economics
Immunotherapy
Infliximab -- therapeutic use
Interleukin-6 -- antagonists & inhibitors
Protein Kinase Inhibitors -- therapeutic use
Randomized Controlled Trials as Topic
Rituximab -- therapeutic use
Treatment Outcome
Tumor Necrosis Factor-alpha -- antagonists & inhibitors
Value-Based Purchasing
Humans
United States